Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Megna

Showing results (241-250 of 251) with videos related to

Pageof 26
Sort By:
Plos One|August 14, 2020
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasisEmanuele Scala, Matteo Megna, Paolo Amerio, et al.
Dermatologic Therapy|October 22, 2021
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) studyDelia Colombo, Luca Bianchi, Gabriella Fabbrocini, et al.
International Journal of Dermatology|May 24, 2022
Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approachClara De Simone, Paolo Dapavo, Piergiorgio Malagoli, et al.
Frontiers in Medicine|August 24, 2023
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, et al.
The Journal of Dermatological Treatment|May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Dermatology and Therapy|April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Dermatology and Therapy|May 13, 2025
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis)Helena Gioacchini, Agnese Rossi, Maria Esposito, et al.
Dermatology Practical & Conceptual|February 28, 2024
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life StudyElena Campione, Fabio Artosi, Ruslana Gaeta Shumak, et al.
Dermatology Practical & Conceptual|November 14, 2025
Brodalumab Efficacy in Psoriasis Patients with Inadequate Response to IL-23 or IL-12/23 Inhibitors: Multicenter Italian Retrospective Analysis - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Maria Concetta Fargnoli, Martina Burlando, et al.
Pageof 26

Showing results (241-250 of 251) with videos related to

Sort By:
Pageof 26
Plos One|August 14, 2020
Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasisEmanuele Scala, Matteo Megna, Paolo Amerio, et al.
Dermatologic Therapy|October 22, 2021
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) studyDelia Colombo, Luca Bianchi, Gabriella Fabbrocini, et al.
International Journal of Dermatology|May 24, 2022
Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approachClara De Simone, Paolo Dapavo, Piergiorgio Malagoli, et al.
Frontiers in Medicine|August 24, 2023
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, et al.
The Journal of Dermatological Treatment|May 7, 2024
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Dermatology and Therapy|April 23, 2025
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis)Mario Valenti, Luciano Ibba, Sara Di Giulio, et al.
Dermatology and Therapy|May 13, 2025
Gender Influence on Bimekizumab Response in Patients with Psoriasis: Results of a Real-World Multicenter Retrospective Study-IL PSO (Italian Landscape PSOriasis)Helena Gioacchini, Agnese Rossi, Maria Esposito, et al.
Dermatology Practical & Conceptual|February 28, 2024
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Pharmaceuticals (Basel, Switzerland)|October 26, 2024
Fast Clinical Response of Bimekizumab in Nail Psoriasis: A Retrospective Multicenter 36-Week Real-Life StudyElena Campione, Fabio Artosi, Ruslana Gaeta Shumak, et al.
Dermatology Practical & Conceptual|November 14, 2025
Brodalumab Efficacy in Psoriasis Patients with Inadequate Response to IL-23 or IL-12/23 Inhibitors: Multicenter Italian Retrospective Analysis - IL PSO (Italian Landscape Psoriasis)Diego Orsini, Maria Concetta Fargnoli, Martina Burlando, et al.
Pageof 26